TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05083156

Intervention type: OTHER
Intervention: Diet Change
Description: Observation Cohort will be observed for treatment response to elimination of cow's milk
Study: NCT02121041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone 12.5 mg or 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan 50 mg or 100 mg
Study: NCT03561753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
Description: The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
Study: NCT02990702

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study: NCT01334879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab 2.0 mg
Description: Intravitreal ranibizumab (2.0 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab 2.0 mg
Description: Intravitreal ranibizumab (2.0 mg)
Study: NCT00979407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2340272A
Description: Two intramuscular injections at Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2340274A
Description: Two intramuscular injections at Day 0 and Day 21
Study: NCT02881554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SC SPECT/CT
Study: NCT03198078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (OPC-34712)
Description: Once-daily, tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Once-daily, tablets
Study: NCT01391013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Oral administration of tablet ritonavir 100 mg once daily at the same time, within 30 minutes after food for 48 weeks
Study: NCT02881554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SC SPECT/CT
Study: NCT01391013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Oral administration of tablet ritonavir 100 mg once daily at the same time, within 30 minutes after food for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 nucleoside reverse transcriptase inhibitors (NRTIs)
Description: 2 NRTIs will be administered as per the package inserts.
Study: NCT02881554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sulfur Colloid
Description: Given IV
Study: NCT02055339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel heated humidified high flow nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InfantFlow/RAM nasal continuous positive airway pressure
Study: NCT01435356

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recMAGE-A3 + AS15 ASCI
Description: 5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
Study: NCT03198078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily, tablets
Study: NCT01400165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
Study: NCT01435356

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
Study: NCT01400165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pindolol
Description: each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Collection
Description: Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Collection
Description: Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Collection
Description: Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
Study: NCT01166646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Proprionate Lotion 0.05%
Description: Apply 3.5 grams twice daily for 1-2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Halobetasol Proprionate Cream 0.05%
Description: Apply 3.5 grams twice daily for 1-2 weeks
Study: NCT02689557

Intervention type: OTHER
Group type: OTHER
Intervention: plethysmography
Description: Validate the measurement made by electroactive polymer sensors (plethysmography) during walking tests in venous insufficient subjects and healthy subjects by comparing the measurement made by the reference technique by mercury gauge.
Study: NCT03075228

Intervention type: DEVICE
Intervention: IntelliCap
Description: Sampling of the small intestine using a samling capsule.

Intervention type: DEVICE
Intervention: IntelliCap
Description: Sampling of the small intestine using a samling capsule.
Study: NCT01143441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAC-HYP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAC-HYP
Study: NCT00860444

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Educational and Counseling Program
Description: Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Educational and Counseling Program
Description: Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
Study: NCT04720001

Intervention type: DRUG
Intervention: Florbetaben F18
Description: A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection

Intervention type: DEVICE
Intervention: PET
Description: PET Scan for brain imaging
Study: NCT02843425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Diet
Description: Participants follow their normal diet (not including beans for 8 weeks)
Study: NCT02314494

Intervention type: BEHAVIORAL
Intervention: ProAsk
Description: The intervention is a computer programme ProActive Assessment of Overweight Risk to identify infants at risk of developing childhood overweight and obesity. Parents of infants identified as at risk will be offered strategies for prevention by UK health visitors (public health nurses)
Study: NCT04888533

Intervention type: OTHER
Intervention: EHSSA- An Efficient and Holistic/Heuristic Semi-structured Suicide Assessment Tool
Description: EHSSA will be used to evaluate every patient for suicide risk.
Study: NCT04201795

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laser
Description: laser with no emision will applied

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure and traction tecnique
Description: pressure and traction in plantar fascia with hands will be applied
Study: NCT02843425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Diet
Description: Participants follow their normal diet (not including beans for 8 weeks)
Study: NCT04692584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Lullaby Group
Description: Approximately 15 seconds before the vaccination, each baby's mother began to sing a lullaby. Infant's mother continued to sing lullabies until all the vaccinations, which were given immediately after the BCG vaccination, were completed. Each mother touched her baby's hands and body while singing a lullaby and hugged her baby after the procedure. All the mothers sang the same lullaby, Sleep and Grow. Mothers were reminded of the words to the lullaby before vaccine administration.
Study: NCT03310086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional fixed appliance
Description: aligning and leveling of lower anterior teeth using traditional fixed appliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional fixed appliance
Description: aligning and leveling of lower anterior teeth using traditional fixed appliance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticision
Description: Corticison, cortical bone incision without flap elevation, will be applied to the lower anterior teeth
Study: NCT02767934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05393349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowering the patient and caregiver for early and safe discharge of patients with geriatric hip fractures
Description: Orthopaedic surgeon, geriatrician, physiotherapists, occupational therapists, and nurses will make videos (each 3-5 minutes long) which are available to the patients and caregivers during both the hospitalization period and after discharge. They will complement the therapists' training sessions and allow revision of the contents by the patients and caregivers anytime. The patients and caregivers will be asked to complete an assessment after they view the videos to reinforce the knowledge they learn in the videos. Caregivers can be patient's relatives, friends or domestic helper who can commit to visiting the patient at least two days per week during the early discharge period.
Study: NCT00640458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Study: NCT03144765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Total Mesorectal Excision (taTME)
Description: Study procedures consist in 1-team (sequential) or 2-team (combined) low anterior resection with transanal TME using laparoscopic or robotic abdominal assistance.
Study: NCT01497717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab (Humira)
Description: Open label pilot trial.~The study includes 3 phases :~1. Open label treatment period of 24 weeks.~2. Extension follow -up (3 years): Patients who responded well to study drug and their disease relapsed within the first 12 weeks following study drug interruption will be eligible to receive the study drug for 3 years in order to comply with the Israeli Ministry of Health requirements.~3. Safety follow-up: For patients who withdraw from either the open label treatment period or extension period, for another 24 weeks.
Study: NCT03342014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: 3DPD and UAD acquisitions (10 min)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
Study: NCT00643773

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: capsules are 0.5g, subjects take 5 capsules with every main meal for 6 months In total this is 15 capsules per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat flour
Description: Wheat flour
Study: NCT02915796

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF + CD133(+) cells
Description: Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous transluminal angioplasty (PTA)
Description: Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: percutaneous transluminal angioplasty (PTA)
Description: Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous transluminal angioplasty (PTA)
Description: Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.
Study: NCT02002390

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fingolimod
Description: A sphingosine-1-phosphate receptor regulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: A sphingosine-1-phosphate receptor regulator
Study: NCT01806558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular Breast Imaging
Description: Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
Study: NCT02843425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navy Beans (Canned)
Description: Participants add 1/2 cup of canned beans per day to their diets for the first 2 weeks. This is increased to 1 cup per day for the following 6 weeks of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Navy Beans (Canned)
Description: Participants add 1/2 cup of canned beans per day to their diets for the first 2 weeks. This is increased to 1 cup per day for the following 6 weeks of the study.
Study: NCT02333474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV mix vaccine
Description: MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), BCG (Bacille Calmette-Guerin vaccine), measles, Serratia and pneumococcus. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study: NCT02017106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous Laser ablation and concomitant phlebectomies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous Laser ablation and concomitant phlebectomies
Study: NCT00640458

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06440863

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Patients undergoing total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip arthroplasty
Description: Patients undergoing total hip arthroplasty
Study: NCT02654015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo MIES
Description: Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Subjects will receive best medical management for intracranial hemorrhage
Study: NCT01142661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin Mesylate: A dose of 1.4 mg/m\^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
Study: NCT02937506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The intervention is to use propofol as anesthesia during a colonoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Plus Midazolam
Description: The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
Study: NCT00658957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin-collagen sponge
Description: 5 × 5 cm sponge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo collagen sponge
Description: 5 × 5 cm sponge
Study: NCT00464139

Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: Laparoscopy
Study: NCT00496262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Fibrinogen Concentrate
Description: Single intravenous infusion of 70 mg/kg body weight
Study: NCT02193607

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT-O
Description: Artificial mesh belt is placed in the middle urethra to provide support to remain no leak

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Improved reconstruction pelvic surgery
Description: Repair of severe pelvic organ prolapse with mesh.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Improved reconstruction pelvic surgery
Description: Repair of severe pelvic organ prolapse with mesh.
Study: NCT01922960

Intervention type: OTHER
Group type: OTHER
Intervention: micro-imaging
Description: micro-imaging
Study: NCT03330860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Twelve clips regarding maternal and neonatal health topics
Description: Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Clip
Description: Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
Study: NCT03904901

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, ingest with water and drink before bed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
Study: NCT02305173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Dexamethasone
Description: One dose of intravenous dexamethasone (8 mg) 60 minutes before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous salin water
Description: Patients of the control group received homologated placebo 60 minutes before surgery.
Study: NCT00791986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULB , LB
Description: ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.~LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULB , LB
Description: ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.~LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.
Study: NCT02518607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGB-BP-3
Description: Treatment of CDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGB-BP-3
Description: Treatment of CDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGB-BP-3
Description: Treatment of CDI
Study: NCT03202888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: QuesGen-created mobile responsive website tool, Family Input for Quality and Safety.
Study: NCT02758171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin